MentalHealthDaily

Multiple Sclerosis Personalized Therapy: 70% Delphi Consensus

by GLOOM

MHD featured image for personalized multiple sclerosis therapy consensus.

An Italian multiple sclerosis Delphi panel reached consensus on 116 of 166 votes, meaning 70% of expert votes aligned and 30% still exposed disagreement about personalized therapy, patient involvement, and treatment sequencing.1 The result supports individualized MS treatment planning, but it is consensus evidence rather than proof that one disease-modifying therapy fits every high-risk patient. …

GLP-1 Drugs for Parkinson’s: Lixisenatide Signal, Exenatide Miss

by GLOOM

Stylized illustration representing GLP-1 receptor agonists being investigated as potential disease-modifying treatments for Parkinson's disease.

Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …